OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round. Plutus Investment Group LLP led the round, with participation from new and existing investors…
OXFORD, UK – 20th March 2023 – Oxford Cancer Biomarkers (OCB) and OncoHelix today announce a new partnership to offer OCB’s advanced genetic test in Canada for screening and detection of people at risk for colorectal cancer. Based on ground-breaking…
OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI award from the NHS AI Lab (joint unit of teams from the Department of Health and Social Care and NHS…
ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED). Independent study publication highlights patient benefits, cost-savings and opportunity for ToxNav® to address potential health inequalities in current approaches to DPYD testing.…
OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has been appointed Non-Executive Chair of Oxford Cancer Biomarkers Ltd. She will take a leading role in helping the company achieve…
Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product OXFORD, UK – July 19th, 2021 – Oxford Cancer Biomarkers (OCB), a pioneer in precision medicine, today announced it has received a CE mark for OncoProg…
Oxford Cancer Biomarkers Ltd is pleased to announce that Kyoung Mee Lee has joined our Board of Directors. OXFORD, UK – April 29th, 2021 – Oxford Cancer Biomarkers Ltd is pleased to announce that Kyoung Mee Lee has joined our…
Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ® OXFORD, UK – April 21st, 2021 – OncoProg ® is a cutting-edge digital pathology prognosis tool that provides a more complete understanding of…
Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal Cancers. This milestone represents a significant step forward for OCB and the ToxNav ® brand. ToxNav ® is OCB’s flag…
Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen operations and support continued growth. This follows the accelerating adoption of ToxNav® a comprehensive genetic blood test that identifies cancer…